ZQZhihai Qin

Zhihai Qin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhihai Qin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    B‐cells and IL‐4 promote methylcholanthrene‐induced carcinogenesis but there is no evidence for a role of T/NKT‐cells and their effector molecules (Fas‐ligand, TNF‐α, perforin)

    by Thomas Kammertoens, Zhihai Qin, Dana Briesemeister, Albert Bendelac, Thomas Blankenstein

    Mice deficient either in subtypes of immune cells, cytokines or lytic pathways have been subjected to chemical carcinogenesis by methylcholanthrene to evaluate whether these components of the immune system affect tumor development. Inbred mice of the same genotype but from different sources differed in tumor development in magnitude comparable to that previously attributed to differences in immunocompetence. This suggested that genetic drift between separate inbred colonies of mice and/or environmental factors (e.g., transport of the animals) influenced carcinogenesis. Therefore, littermates were used as control in subsequent experiments. Although deficiency of T-cells, NKT-cells, perforin, Fas-ligand, TNF-α-receptor failed to reveal significant differences in tumor development, the presence of B-cells and IL-4 enhanced tumor development under similar experimental conditions.


    • 15 July 2003
      • Vol. 63  (14) , 4095-100

    A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.

    by Zhihai Qin, Johannes Schwartzkopff, Felicia Pradera, Thomas Kammertoens, Barbara Seliger, Hanspeter Pircher, Thomas Blankenstein

    It is thought that tumor rejection by CD8(+) T-cell effectors is primarily mediated by direct killing. We show that rejection of different tumors (fibrosarcoma, ras-transformed fibroblasts, colon carcinoma, and plasmacytoma) by CD8(+) T cells is always preceded by inhibition of tumor-induced angiogenesis. Angiostasis and tumor rejection were observed in perforin but not in IFN-gamma-deficient mice. Furthermore, adoptive transfer of tumor-specific CD8(+) T cells from IFN-gamma-competent mice inhibited angiogenesis of lung metastases in comparison to those from IFN-gamma gene-deficient mice. Taken together with our previous findings, we conclude that IFN-gamma-dependent antiangiogenesis is a general mechanism involved in tumor rejection by CD4(+) and CD8(+) T-cell effectors.


  • Open Access

    Inhibition of Methylcholanthrene-induced Carcinogenesis by an Interferon γ Receptor–dependent Foreign Body Reaction

    by Zhihai Qin, Hye-Jung Kim, Jens Hemme, Thomas Blankenstein

    The foreign body reaction is one of the oldest host defense mechanisms against tissue damage which involves inflammation, scarring, and encapsulation. The chemical carcinogen methylcholanthrene (MCA) induces fibrosarcoma and tissue damage in parallel at the injection site. Tumor development induced by MCA but not due to p53-deficiency is increased in interferon-γ receptor (IFN-γR)–deficient mice. In the absence of IFN-γR, MCA diffusion and DNA damage of surrounding cells is increased. Locally produced IFN-γ induces the formation of a fibrotic capsule. Encapsulated MCA can persist virtually life-long in mice without inducing tumors. Together, the foreign body reaction against MCA prevents malignant transformation, probably by reducing DNA damage. This mechanism is more efficient in the presence of IFN-γR. Our results indicates that inflammation and scarring, both suspected to contribute to malignancy, prevent cancer in certain situations.


    • 15 May 2002
      • Vol. 62  (10) , 2856-60

    Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors.

    by Zhihai Qin, Christina Harders, Xuetao Cao, Christoph Huber, Thomas Blankenstein, Barbara Seliger

    The lack of transporter-for-antigen-presentation (TAP)-1 expression by tumor cells prevents the processing and presentation of MHC class I-restricted tumor antigens. This could affect T-cell-dependent tumor immunity in either the priming or the effector phase. We have established TAP1(+) and TAP1(-) tumor cell lines using ras-transformed NIH3T3 fibroblasts. Impaired TAP1 expression by tumor cells increased their tumorigenicity in immunocompetent, but not in T-cell-deficient, mice. For the generation of tumor immunity, TAP1 expression was not necessary on tumor cells used for vaccination. However, in previously immunized mice TAP1(+) tumor cells were more efficiently rejected than were TAP1(-) tumor cells. CD8(+) T cells infiltrated both TAP1(+)- and TAP1(-)-challenge tumors and were required for tumor rejection. In mixed tumor/lymphocyte culture, TAP1 expression by tumor cells significantly increased the IFN-gamma production of antigen-specific spleen cells from immunized, but not from naive, mice. Thus, the lack of TAP1 expression did not change the immunogenicity of tumor cells. It may enable tumor cells to escape T-cell recognition during the effector phase of an antitumor immune response.


  • Open Access

    Decreased generation of anti-tumor immunity after intrasplenic immunization

    by Sophie Cayeux, Zhihai Qin, Bernd Dörken, Thomas Blankenstein